المؤلفون: Hamzah Khan, Shubha Jain, Reid C. Gallant, Muzammil H. Syed, Abdelrahman Zamzam, Mohammed Al-Omran, Margaret L. Rand, Heyu Ni, Rawand Abdin, Mohammad Qadura

المصدر: Journal of Personalized Medicine ; Volume 11 ; Issue 8

مصطلحات موضوعية: aspirin, resistance, non-sensitivity, antiplatelet, atherosclerosis, light transmission aggregometry, Plateletworks ®, psy, envir

الوصف: Aspirin (ASA) therapy is proven to be effective in preventing adverse cardiovascular events ; however, up to 30% of patients are non-sensitive to their prescribed ASA dosage. In this pilot study, we demonstrated, for the first time, how ASA non-sensitivity can be diagnosed using Plateletworks®, a point-of-care platelet function test. Patients prescribed 81 mg of ASA were recruited in a series of two successive phases—a discovery phase and a validation phase. In the discovery phase, a total of 60 patients were recruited to establish a cut-off point (COP) for ASA non-sensitivity using Plateletworks®. Each sample was simultaneously cross-referenced with a light transmission aggregometer (LTA). Our findings demonstrated that > ; 52% maximal platelet aggregation using Plateletworks® had a sensitivity, specificity, and likelihood ratio of 80%, 70%, and 2.67, respectively, in predicting ASA non-sensitivity. This COP was validated in a secondary cohort of 40 patients prescribed 81 mg of ASA using Plateletworks® and LTA. Our data demonstrated that our established COP had a 91% sensitivity and 69% specificity in identifying ASA non-sensitivity using Plateletworks®. In summary, Plateletworks® is a point-of-care platelet function test that can appropriately diagnose ASA non-sensitive patients with a sensitivity exceeding 80%.

العلاقة: https://doi.org/10.3390/jpm11080813Test

الإتاحة: https://doi.org/10.3390/jpm11080813Test

المؤلفون: Shubha Jain, Mohammad Qadura, Rawand Abdin, Krishna K. Singh, Muzammil H. Syed, Abdelrahman Zamzam, Jason Valencia, Hamzah Khan

المصدر: Diagnostics
Diagnostics, Vol 10, Iss 230, p 230 (2020)
Volume 10
Issue 4

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Clinical Biochemistry, Ischemia, quantitative polymerase chain reaction, 030204 cardiovascular system & hematology, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, microRNA, medicine, In patient, chronic limb threatening ischemia, next generation sequencing, lcsh:R5-920, business.industry, Confounding, Plasma levels, MicroRNA Profile, medicine.disease, body regions, 030104 developmental biology, Real-time polymerase chain reaction, Cohort, lcsh:Medicine (General), business

الوصف: Chronic limb-threatening ischemia (CLTI) results in devastating complications such as lower-limb amputations. In this study, a genome-wide plasma microRNAs (miRNA) sequencing was performed to identify miRNA(s) associated with CLTI. Blood samples were collected from early stage CLTI patients (ABI <
0.9) and non-PAD controls (ABI &ge
0.9) for 3 experiments: discovery phase (n = 23), confirmatory phase (n = 52) and validation phase (n = 20). In the discovery phase, next generation sequencing (NGS) was used to identify miRNA circulating in the plasma CLTI (n = 13) patients, compared to non-PAD controls (n = 10). Two down-regulated miRNAs (miRNA-6843-3p and miRNA-6766-5p) and three upregulated miRNAs (miRNA-1827, miRNA-320 and miRNA-98-3p) were identified (&ge
2-fold change). In the confirmatory phase, these 5 deregulated miRNAs were further investigated in non-PAD (n = 21) and CTLI (n = 31) patients using qRT-PCR. Only miRNA-1827 was found to be significantly upregulated (&ge
3-fold, p-value <
0. 001) in the CLTI group. Lastly, to minimize the influence of confounding factors, miRNA-1827 plasma levels were validated in a third cohort of CLTI patients (n = 10) matched to non-PAD controls (n = 10). Our analysis demonstrated that miRNA-1827 expression was increased in the CLTI cohort (&ge
2-folds, p-value <
0.001). In summary, circulating miRNA-1827 is significantly elevated in patients with CLTI.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fbe8aa7b8d65202efd6d6598beb9784Test
http://europepmc.org/articles/PMC7235988Test